Shortly after in 2011, sales began to decline due to the development of a more effective treatment, ranibizumab (a monoclonal antibody, Novartis) being developed and sold, and the off-label use of the cheaper Bevacizumab.
Shortly after in 2011, sales began to decrease due to the creation of a more efficient treatment, ranibizumab (a monoclonal antibody, Novartis), being created and sold, and the non-prescribed use of the cheaper Bevacizumab.